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Abstract
Purpose Ambulatory peripheral vascular interventions
have been steadily increasing. In ambulatory procedures,
4F devices might be particularly useful having the potential
to reduce access-site complications; however, further evi-
dence on their safety and efficacy is needed.
Materials and Methods BIO4AMB is a prospective, non-
randomized mulitcentre, non-inferiority trial conducted in
35 centres in Europe and Australia comparing the use of
4F- and 6F-compatible devices. The main exclusion criteria
included an American Society of Anaesthesiologists
class C 4, coagulation disorders, or social isolation. The
primary endpoint was access-site complications within
30 days.
Results The 4F group enrolled 390 patients and the 6F
group 404 patients. Baseline characteristics were similar
between the groups. Vascular closure devices were used in
7.7% (4F group) and 87.6% (6F group) of patients. Patients
with vascular closure device use in the 4F group were
subsequently excluded from the primary analysis, resulting
in 361 patients in the 4F group. Time to haemostasis was
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longer for the 4F group, but the total procedure time was
shorter (13.2 ± 18.8 vs. 6.4 ± 8.9 min, p\ 0.0001, and
39.1 ± 25.2 vs. 46.4 ± 27.6 min, p\ 0.0001). Discharge
on the day of the procedure was possible in 95.0% (4F
group) and 94.6% (6F group) of patients. Access-site
complications were similar between the groups (2.8% and
3.2%) and included predominantly groin haematomas and
pseudoaneurysms. Major adverse events through 30 days
occurred in 1.7% and 2.0%, respectively.
Conclusions Ambulatory peripheral vascular interventions
are feasible and safe. The use of 4F devices resulted in
similar outcomes compared to that of 6F devices.
Keywords Peripheral vascular intervention 
Ambulatory treatment  4F  Access-site complication
Introduction
The numbers of peripheral vascular interventions (PVIs)
have increased substantially worldwide [1–4]. Tradition-
ally performed on an inpatient basis, in order to free up
limited resources and save costs, clinicians have to evalu-
ate the concept of ambulatory procedures [5–7]. Although
several reports have demonstrated ambulatory procedures
to be safe and efficient, further evidence is needed to
ensure the clinical and economic value of outpatients’
management of PVIs [7]. Furthermore, most published data
available refer to 6 French (F) devices [6, 8]; however, 4F
devices might be particularly useful in this setting as this
low-profile approach can avoid the use of vascular closure
devices (VCDs), and thus has the potential for reducing
access-site-complications (ASCs) [9, 10]. The 4-EVER
trial confirmed the successful use of 4F devices without the
need for closure devices with only 3.3% ASCs [11].
To further assess how the use of smaller sheath sizes
may affect the ambulatory treatment and the rate of ASCs,
the ‘‘BIOTRONIK 4French for AMBulatory Peripheral
Intervention (BIO4AMB)’’ study was initiated in Europe
and Australia for evaluating the non-inferiority of ambu-




BIO4AMB is a prospective, non-randomized multicentre,
non-inferiority trial conducted in 35 centres in Austria,
Belgium, France, Switzerland, Denmark, Germany and
Australia. Equal numbers of patients in the 4F and 6F
groups were intended to be enrolled at each site.
The full list of inclusion- and exclusion criteria is
available at ClinicalTrials.gov:NCT03044002. Briefly,
patients with infrainguinal arterial lesions suitable to be
treated with an endovascular intervention in an ambulatory
setting, those who were able to walk and those who signed
informed consent could be included. Main exclusion cri-
teria were American Society of Anaesthesiologists class
C 4, coagulation disorders, or social isolation during the
first night. Patients’ assessments were performed at base-
line and during the procedure, discharge, and at 30 days.
The 30-day visit was scheduled as office visit, but tele-
phone follow-ups were accepted if this was not possible.
The study was conducted according to the current ver-
sion of the Declaration of Helsinki, ISO14155:2011,
according to national and local requirements, and was
approved by the sites’ ethic committees. Monitoring of
endpoint-related data was performed for at least 25% of
patients randomly selected. A clinical events committee
adjudicated all endpoint-related adverse events.
Devices and Procedures
The introducer sheaths could be selected at the physician’s
discretion. In the 4F group, the Passeo-18 uncoated bal-
loon, Passeo-18 Lux drug-coated balloon and Pulsar-18
stent could be used (all Biotronik AG, Buelach, Switzer-
land), but no VCD was permitted. In the 6F group, the
choice of devices ought to reflect the standard of care, and
the use of VCDs was optional (Supplementary Table 1).
Whether a 4F- or 6F-access was used was left at the
physician’s discretion, provided that the instructions for
use were respected.
The access ought to be ultrasound guided, if available.
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Endpoints and Definitions
The primary endpoint was ASCs within 30 days (including
haemostasis strategy failure), defined as groin hematoma
([ 5 cm in diameter, visible by sonography, and hae-
moglobin decrease\ 3 g/dL), pseudoaneurysm, groin or
retroperitoneal bleeding (defined as requiring acute inter-
vention for haemostasis, need for blood transfusions, or
haemoglobin decrease[ 3 g/dL), arteriovenous fistula (as
evidenced by colour coded sonography), arterial dissec-
tions at the access site (visible with angiography or
sonography as a membrane causing stenosis in the vessel
lumen), thrombosis, or closure device-related ASC.
Secondary endpoints were procedural success (defined
as no change to a larger sheath size and/or second puncture
site), ambulatory failure (defined as unplanned overnight
hospitalization), time to haemostasis, time to discharge,
VCD failure and related complication, reinterventions,
Rutherford class, and ankle brachial index (ABI) [12] at
30 days. Major adverse events (MAEs) were defined as a
composite of freedom from 30-day device- or procedure-
related mortality, major target limb amputation and clini-
cally driven TLR.
Statistical Analyses
The sample size of BIO4AMB was based on non-inferi-
ority on the primary endpoint ASC with a non-inferiority
margin of 2% assuming an ASC-rate of 5% in the 6F group
and 3% in the 4F group [11, 13, 14]. A total of 792 patients
(377 ? 19 per group) were scheduled to be enrolled
assuming a one-sided alpha of 0.025, a power of 80% and
5% dropouts.
The primary analysis consists of the modified intention-
to-treat-population that excludes patients treated with a
VCD in the 4F group, as no VCD is 4F compatible and
using a 6F-closure device contradicts the 4F approach. The
secondary analysis is based on the intention-to-treat pop-
ulation (Supplementary Tables 2–5). ABI-values[ 1.3
were censored.
For quantitative variables, the mean values, standard
deviation, and 95% confidence interval for the mean were
calculated as applicable, and for qualitative variables,
absolute and relative frequencies. Calculations were based
on the available data. The 4F and 6F groups were com-
pared using the Chi-square, Wilcoxon, and T tests. A p-
value of\ 0.05 was considered statistically significant.
In a posthoc-analysis, propensity score matching was
performed for the factors gender, body-mass index,
smoking, hypertension, diabetes, critical limb ischaemia,
below-the-knee (BTK) lesions, calcification at the puncture
site, antegrade versus retrograde access, previous puncture
at the same site, procedure time, antiplatelet and
anticoagulation agents, and for one study site that enrolled
35% of the patients and hence exceeded the common
threshold of a maximum of 20–30% of patients enrolled
per site (Supplementary Table 6).
In another posthoc analysis, subgroup analyses for
freedom from ASC, MAE, and patients discharged on the
same day of the procedure were performed for age[ 65
years, females, diabetics, femoral lesions, popliteal lesions,
BTK lesions, and antegrade or retrograde access. All
analyses were performed using SAS version 9.4 (SAS
Institute Inc, Cary, NC, USA).
Results
Overall, 794 patients were included, wherein 390 were
treated with a 4F device and 404 with a 6F device. Patients
who received a VCD in the 4F group (n = 29, 7.4%) were
excluded from the primary analysis (that thus encompasses
361 patients with 516 lesions), but were included in the
secondary analysis (Supplementary Tables 2–5).
The baseline characteristics were similar between the
groups; patients were 70 ± 11 (4F group) and
69 ± 11 years old (6F group), and 29.4% and 33.2% had
diabetes. There was only a small difference between the
groups regarding to hyperlipidaemia (59.3% vs. 70.5%,
p = 0.001) and renal disease (22.4% vs. 16.1%, p = 0.019)
(Table 1). Lesions were located in the superficial femoral
artery in 57% in both the groups; BTK lesions were present
more frequently in the 4F group (19.0% vs. 13.2%,
Table 1 Baseline patient characteristics
4F N = 361 6F N = 404 p-value
Age, years 70 ± 11 69 ± 11 0.235
Male 260 (72.0) 310 (76.7) 0.136
Smoking 274 (75.9) 310 (76.7) 0.787





Hypertension 289 (80.1) 326 (80.7) 0.825
Hyperlipidaemia 214 (59.3) 285 (70.5) 0.001
Diabetes mellitus 106 (29.4%) 134 (33.2%) 0.258
Insulin dependent 45 (12.5) 42 (10.4)
Renal insufficiency* 81 (22.4) 65 (16.1) 0.026
History of PAD 206 (57.1%) 243 (60.1%) 0.387
Previous PVI/ surgeries 167 (46.3%) 196 (48.5%) 0.533
BMI-body mass index, PAD, peripheral artery disease, PVI, periph-
eral vascular intervention
Data are displayed as mean ± standard deviation or n (%)
*According to site-assessment
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p = 0.008). Furthermore, lesions treated with a 4F device
were less calcified (moderate/heavy calcification in 40.1%
vs. 47.1%, p = 0.002) (Table 2).
Vessel puncture was more frequently ultrasound guided
in the 4F group (83.9% vs. 77.8%, p = 0.032), VCD
devices were used in 87.6% (353/403) of cases in the 6F
group, and additional manual compression or manual
compression devices were required in 42.8% (151/353).
Overall, time to haemostasis was longer in the 4F group
(13.2 ± 18.8 min vs. 6.2 ± 8.9 min, p\ 0.0001), and
procedure time shorter (39.1 ± 25.2 min vs.
46.4 ± 27.6 min, p\ 0.0001) (Table 3). Discharge on the
day of procedure was nearly identical between the groups
(95.0% vs. 94.6% p = 0.782); time to discharge was
7.9 ± 12.1 h vs. 7.8 ± 10.8 h, p = 0.257 (5.9 ± 2.0 h vs.
6.2 ± 2.1 h, p = 0.267, excluding patients with ambula-
tory failure). Adverse events in patients with ambulatory
failures are provided in Supplementary Table 7.
At 30 days, five patients were lost-to-follow-up in the
4F group, and four patients had died in the 6F group (one
sudden death, one worsening of peripheral artery disease,
one cardiac arrest and one myocardial infarction). There
was no significant difference in ASCs in the intention-to-
treat or in the propensity-score matched cohort. ASCs
occurred in 2.8% of patients in the 4F group and 3.2% of
patients in the 6F group, p = 0.729 and pnon-inferiority-
= 0.0253 (3.3% and 2.6% in the propensity matched
cohort respectively, p = 0.627), and were predominantly
caused by groin hematoma and pseudoaneurysms
(Table 4). In the 6F group, all but one ACSs occurred in
patients treated with a VCDs (3.4%, 12/353).
MAEs and reinterventions rates (clinically-driven target
lesion revascularization) were also similar (1.7% vs. 2.0%,
p = 0.794 and 1.7% vs.1.5%, p[ 0.999, respectively)
(Fig. 1). Furthermore, there was no significant difference in
ASC, MAE and ambulatory failure in the subgroups, as
specified in Table 5.
From baseline to 30 days, ABI improved from
0.75 ± 0.19 (n = 225) to 0.96 ± 0.22 (n = 215) in the 4F
group and from 0.72 ± 0.22 (n = 331) to 0.96 ± 0.18
(n = 311) in the 6F group. Using paired data, ABI
improved by 0.22 ± 0.21 (n = 185) and 0.25 ± 0.24
(n = 282), respectively. Furthermore, Rutherford class
improvement was nearly identical in the groups (Fig. 2).
Anticoagulation/ antiplatelet therapy from pre-procedure
through 30 days is provided in Supplementary Table 8.
Discussion
The BIO4AMB trial confirmed that the ambulatory treat-
ment of peripheral artery disease is safe and effective
regardless of whether 4F or 6F devices are used. ASC and
MAE rates were low and approximately 95% of patients
could be discharged on the day of the procedure (5%
ambulatory failure).
Procedure
Despite the use of VCDs in 87.4% of cases, additional
treatment was required in 42.8% in the 6F group. Overall,
manual compression time and time to haemostasis were
longer for the 4F group, but total procedure time shorter.
This is not unexpected since previous studies have reported
a longer time to haemostasis with compression than with
VCDs [15, 16]. Nevertheless, the manual compression time
was shorter than the recommended 15 to 20 min reported
previously for larger sheath sizes [15]. Furthermore, one
may speculate that there is even more scrutiny in
haemostasis for avoiding late complications in the ambu-
latory setting.
Ambulatory Failure
Patients prefer to be discharged on the same day as the
procedure [7, 17]. The use of manual compression may
impact the chance to be discharged on the same day and






Lesion location N = 517 N = 613
Common femoral 23 (4.4) 32 (5.2) 0.548
SFA 294 (56.9) 347 (56.6) 0.930
Popliteal artery 73 (14.1) 108 (17.6) 0.110
BTK 98 (19.0) 81 (13.2) 0.008
Other* 29 (5.6) 45 (7.3) 0.241
Calcification N = 511 N = 607 0.002
Moderate 101 (19.8) 179 (29.5)
Heavy 104 (20.4) 107 (17.6)
TASC classification N = 512 N = 607 0.328
A 130 (25.4) 154 (25.4)
B 173 (33.8) 234 (38.6)
C 126 (24.6) 129 (21.3)
D 83 (16.2) 90 (14.8)
Thrombus present N = 516 N = 609 0.380
70 (13.6) N = 72 (11.8)
Data are displayed as mean ± standard deviation or n (%)
*4F: 9 Arteria femoralis profunda, 8 bypass grafts, 7 iliac arteries, 2
lesions extending in two vessels, 6F: 8 Arteria femoralis profunda, 10
bypass grafts, 24 iliac arteries, and one stented artery
according to site-assessment. BTK, below-the-knee, SFA, superfi-
cial femoral artery
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[ 1 vascular access 5 (1.4) 5 (1.2) [ 0.999
Access N = 366 N = 410 0.002
Antegrade 259 (70.8) 246 (60.0)
Retrograde 107 (29.2) 164 (40.0)
Puncture ultrasound guided 307 (83.9%) 319 (77.8%) 0.032
Calcification at puncture site N = 366 N = 410 0.001
None 175 (47.8%) 136 (33.2%)
Mild 136 (37.2%) 175 (42.7%)
Moderate 39 (10.7%) 77 (18.8%)
Heavy 16 (4.4%) 22 (5.4%)










Devices used N = 958 N = 1171 –
Plain balloon 500 (52.2) 534 (45.6)
Drug-coated balloon 102 (10.6) 217 (18.5)
Stent 346 (36.1) 385 (32.9)
Rotational thrombectomy 0 (0.0) 1 (0.1)
Atherectomy 0 (0.0) 5 (0.4)
Scoring balloon 0 (0.0) 8 (0.7)
Cutting balloon 2 (0.2) 8 (0.7)
Other 8 (0.8) 13 (1.1)
Haemostasis N = 361 N = 403 < 0.0001
VCD only 0 (0) 202 (50.0)
Compression device only 0 (0.0) 0 (0.0)
Manual compression only 147 (40.7) 24 (5.9)
VCD ? compression device 0 (0.0) 23 (5.7)
VCD ? manual compression 0 (0.0) 91 (22.5)
VCD ? compr. device ? manual compression 0 (0.0) 36 (8.9)
Compression device ? manual compression 214 (59.3) 25 (6.7)
Other combinations 0 (0.0) 1 (0.2)
None 0 (0.0) 1 (0.2)
Haemostasis in ASC patients N = 10 N = 13 < 0.0001
VCD only 0 (0.0) 1 (7.7)
Manual compression only 6 (60.0) 0 (0.0)
VCD ? manual compression 0 (0.0) 3 (23.1)
VCD ? compression device ? manual 0 (0.0) 8(61.5)
compression
Compression device ? manual compression 4 (40.0) 1 (7.7)
Manual compression time, min N = 361 N = 402 < 0.0001
9.1 ± 8.8 4.2 ± 7.4
[8.2;10.0] [3.5;4.9] 0.088
Brodmann et al.: Clinical Outcomes of Ambulatory Endovascular Treatment…
123
VCDs may reduce hospital time [15, 16]. In a study by
Akopian et al. [6], only 80% of patients treated with
manual compression were discharged the same day versus
93% of patients treated with VCDs. However, these studies
were mostly performed with sheaths larger than 4F. In our
study, the rate of ambulatory failure was 5% in both the
groups, and thus was within the 0–27.3% range as reported
in the literature [6–8, 18].
Access Site Complications
The use of VCDs may be associated with complications
such as infection, bleeding, pseudoaneurysm, arterial lac-
eration, arteriovenous fistulae, embolization, limb ischae-
mia, thrombosis, pain, dissection and nerve injury [8, 15],
and no data have shown the advantages of VCDs in terms







Without zeros N = 361 N = 179
9.1 ± 8.8 9.6 ± 8.6
[8.2, 10.0] [8.3, 10.8]
Time to haemostasis, min N = 361 N = 403 < 0.0001
13.2 ± 18.8 6.2 ± 8.9
[11.3;15.2] [5.3;7.1]
Procedure time, min N = 359 N = 402 < 0.0001
39.1 ± 25.2 46.4 ± 27.6
[36.5;41.8] [43.8;4923]
Procedure success 358 (99.2) 400 (99.0) [ 0.999
Data are displayed as mean ± standard deviation [95%confidence interval] or n (%)
*excludes patients with VCD who did not require manual compression,
excludes patients in whom no manual compression was performed. ASC, access-site complication, VCD, vascular closure device
Table 4 Clinical outcomes of






Vascular closure device complication 0 (0.0) 10 (2.5) 0.002
N = 356 N = 401
Access-site complications* 10 (2.8) 13 (3.2) 0.729
Groin hematoma 4 (23.5) 4 (15.4) 0.788
Pseudoaneurysm 5 (29.4) 6 (23.1)
Groin-bleeding 1 (5.9) 2 (7.7)
AV-fistula 0 (0.0) 0 (0.0)
Arterial dissection 0 (0.0) 1 (3.8)
Thrombosis 1 (5.9) 0 (0.0)
VCD-related 0 (0.0) 0 (0.0)
Other 6 (35.3) 13 (50.0)





N = 356 N = 402
Major adverse events 6 (1.7) 8 (2.0) 0.794
Procedure- or device related death 0 (0.0) 2 (0.5) 0.501
Major target limb amputation 1 (0.3) 0 (0.0) 0.471
Clinically driven TLR 6 (1.7) 6 (1.5) [ 0.999
Data are displayed as n (%)
*could consist of several of the events below
worsening of peripheral artery disease on day 8 and sudden death on day 16 post-procedure.
AV, arteriovenous; TLR, target lesion revascularization; VCD, vascular closure device
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Therefore, the primary study hypothesis for providing
the non-inferiority of the 4F group compared to the 6F
group, considered a higher ASC-rate in the 6F group using
VCDs. However, the outcomes were nearly identical in the
groups (2.8% vs. 3.2%), as the 6F group had better out-
comes than the predicted 5% ASC-rate. This is likely due
to improvements in VCDs, the recommended ultrasound
guidance, and the fact that participating centres were
experienced high-volume centres [19, 20]. Thus, the study
hypothesis failed slightly (pnon-inferiority = 0.0253 instead
of\ 0.025) as the sample size was too low being based on
a 2% margin of an expected ASC rate of 5% in the 6F
group, which turned out to be lower than expected.
The outcomes might have also been biased by the fact
that VCD use was not permitted in the 4F group. Mean-



















Fig. 1 Access-site complications, major adverse events, re-interven-
tions, and ambulatory failure with 4-French and 6-French sheaths.
There was no significant difference between the groups. ASC, access-
site complication, MAE, major adverse event, TLR, clinically driven
target lesion revascularization
Table 5 Safety and efficacy of
selected subgroups
Endpoint 4F 6F p-value
Age[ 65 years Freedom from ASC (subject based, %) 235 (96.7%) 247 (96.5%) 0.891
MAE (subject based, %) 4 (1.6%) 4 (1.5%) [ 0.999
Same-day discharge 231 (94.3%) 245 (94.6%) 0.880
Female Freedom from ASC (subject based, %) 95 (94.1%) 89 (94.7%) 0.851
MAE (subject based, %) 3 (3.0%) 2 (2.2%) [ 0.999
Same-day discharge 93 (92.1%) 90 (95.7%) 0.287
Diabetics Freedom from ASC (subject based, %) 101 (98.1%) 130 (97.0%) 0.612
MAE (subject based, %) 1 (1.0%) 2 (1.5%) [ 0.999
Same-day discharge 100 (94.3%) 128 (95.5%) 0.676
CFA and SFA Freedom from ASC (subject based, %) 206 (96.7%) 223 (95.7%) 0.580
MAE (subject based, %) 3 (1.4%) 3 (1.3%) [ 0.999
Same-day discharge 206 (95.4%) 221 (94.8%) 0.799
Popliteal Freedom from ASC (subject based, %) 28 (93.3%) 31 (93.9%) 0.922
MAE (subject based, %) 0 (0%) 0 (0%) NA
Same-day discharge 30 (90.0%) 30 (90.9%) 0.902
BTK Freedom from ASC (subject based, %) 36 (100%) 16 (100%) NA
MAE (subject based, %) 1 (2.8%) 0 (0%) [ 0.999
Same-day discharge 34 (91.9%) 16 (100%) 0.241
Antegrade Access Freedom from ASC (subject based, %) 249 (98.0%) 235 (97.1%) 0.503
MAE (subject based, %) 4(1.6%) 4 (1.6%) [ 0.999
Same-day discharge 242 (94.5%) 230 (93.9%) 0.754
Retrograde Access Freedom from ASC (subject based, %) 97 (95.1%) 153 (96.2%) 0.658
MAE (subject based, %) 2 (2.0%) 4 (2.5%) [ 0.999
Same-day discharge 101 (96.2%) 152 (95.6%) 0.813
BTK, below-the-knee; CFA, common femoral artery; NA, not applicable; SFA, superficial femoral artery
Brodmann et al.: Clinical Outcomes of Ambulatory Endovascular Treatment…
123
devices B 7F to decide on the use of VCD based on factors
that may be associated with impaired haemostasis such as
obesity, coagulation disorder, and physician’s experience.
While the comparison of outcomes to other studies is
hampered through different patient population, different
scrutiny in monitoring, and different definitions of ASCs, it
can still be concluded that the ASC-rate of 2.8% in the 4F
group and 3.2% in the 6F group (3.3% and 2.6% in the
matched cohort, respectively) is low and consistent with
the 3.3% rate observed in the 4-Ever trial [11], the 3.5%
rate in the Vascular Quality Initiative [14], the 0–3% major
haematomas reported in a systematic review [7], and lower
than the 11.5% rate reported in a retrospective single centre
study [22], or the 12% of hematoma and closure device
failure reported by Albert et al. [8].
Risk Groups
With our subgroup analyses in elderly, females, diabetics,
femoral, popliteal, and below-the-knee lesions, as well as
for antegrade access, we have demonstrated that even in
these high-risk groups ambulatory treatment is feasible
with a low risk of complications, allowing an early return
to home for a broad patient population.
Limitations
This study has several limitations. It is not randomized;
however, the primary endpoint was tested for potential
confounding effects using propensity matching and did not
reveal a significant difference between the groups (ASC-
rate of 3.3% vs. 2.6% in the matched cohort). The com-
parison to other studies is limited owing to different defi-
nitions of ASCs and the fact that our data were monitored,
whereas other data such as from the vascular surgery’s
Vascular Quality Initiative database are self-reported [14].
Furthermore, no VCDs were permitted in the 4F group
which does not reflect routine use and might have resulted
in biased outcomes. Positive is the high follow-up com-
pliance rate. We did not report on health economic aspects
which are relevant, particularly considering the financial
impact of the use of VCDs, procedure time, discharge time,
and quality of life, as these data will be the subject of an
upcoming publication.
Conclusions
In summary, ambulatory treatment is a valid and safe
option for endovascular treatment of lower-extremity
peripheral arterial disease. 4F-compatible devices show
similar short-term safety when compared to the well-
established 6F devices and are a valid alternative based on
patients’ needs and physicians’ preferences, while avoiding
the additional need for VCDs. Further studies, including
health economic aspects, are needed for better defining the
appropriate patient population that benefits most from the
ambulatory procedures and a minimized hospital stay, and
for determining the cost-effectiveness of 4F-compatible
devices compared to 6F-compatible devices.
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Fig. 2 Rutherford class assessments A Rutherford class at baseline
and 30-day follow-up B Change in Rutherford class at 30-day follow-
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